Navigation Links
Natural Approach to Immune Regulation May Help Transplant Patients

A molecule expressed during pregnancy seems to turn down the immune system, making it more tolerant of welcome visitors such as a fetus or maybe a transplanted heart//, researchers say.

Human leukocyte antigen G, or HLA-G, is a member of a gene family called major histocompatibility complex that provokes an immune response, says Dr. Anatolij Horuzsko, reproductive immunologist at the Medical College of Georgia.

Like an errant child, HLA-G instead promotes tolerance, and researchers have found it can even make other gene family members more accepting, says Dr. Horuzsko, who is presenting his research during the Fourth International Conference on HLA-G July 10-13 in Paris and chairing a session on structure and receptor interaction. His research also is featured in the August issue of the European Journal of Immunology.

The placenta expresses HLA-G from the earliest stages of embryo implantation and the molecule goes away toward the end of pregnancy. Growth factors and cytokines – signaling compounds involved in the development and function of the immune system – bring to the surface inhibitory receptors previously buried inside immune cells so they can interact with the HLA-G.

Amazingly, scientists have documented this natural immunosuppression, to a lesser extent, in at least one more situation: when an organ is transplanted. Dr. Horuzsko wants to augment this natural process so transplant patients won't require a lifetime of generalized immune suppression that puts them at risk for many other diseases.

He has created animal models in which these inhibitory receptors are expressed on the cell surface. Using the same mixture the body uses – cytokines and growth factors – he also gets the receptors expressed on the surface of human cells in a test tube. He gives HLA-G in both situations and studies the response.

In dendritic cells, major orchestrators of the immune response, he has watched how act ivated inhibitory receptors down-regulate the function of stimulators of the immune response also present on the cell surface. Interestingly, the targets are members of the major histocompatibility complex family to which HLA-G belongs.

"These dendritic cells are not defective, but they develop tolerogenic properties, which are not normal for them," says Dr. Horuzsko, who equates modifying the immune response to turning down the volume of a television. "We think we can help them into a tolerogenic pathway by giving HLA-G and get them to ignore the antigen coming from transplanted tissue," he says. Unfortunately, he notes, cancer and some viruses seem capable of similar manipulation.

Using this approach, he has been able to prolong acceptance of skin grafts, which are typically rapidly rejected, sometimes indefinitely.

He's also getting T cells, another major player in the immune response, to express inhibitory receptors. Normally dendritic cells show an invader to T cells which produce cytotoxic T cells to destroy it. But when T cells express the inhibitory receptor, they go silent and may even die.

A long list of other cells that provoke an immune response might be "kept under control" by this approach, Dr. Horuzsko says.

He envisions, in the not too distant future, giving cytokines and growth factors to patients so targeted cells will express inhibitory receptors then delivering a sort of HLA-G manufacturing plant, probably blood-derived stem cells modified to produce it. In patients who already express inhibitory receptors, it may be enough to give only HLA-G. Dr. Horuzsko plans to further investigate this expression that occurs soon after an organ transplant in some patients.

These natural approaches would be used to prepare a patient for transplant and activated when problems with rejection emerge.

"I believe this natural mechanism is a very powerful tool for protecting tissue a llografts from rejection," says Dr. Horuzsko.

(Source: Newswis)
'"/>




Related medicine news :

1. Accuracy of Some Natural Family Planning Methods Questioned .
2. Natural formula for protection against vision loss
3. Naturally Occurring Hormone Can Lead To Miscarriage
4. Treating Leukemia With Natural Cells
5. Natural Sulfur Can Treat Pain From Osteoarthritis
6. Chronic Post-Traumatic Stress Disorder (PTSD) Risk In Young Natural Disaster Survivors
7. Tsunami Unplugged: Natural Disasters Favor the Under-privileged
8. ‘Natural Spring’ Starts A Week Ahead Now Than Before: UNH Scientit
9. An After-Dinner Nap Is A Natural Thing, Scientists Proved
10. The Most Natural Thing in the World
11. Fertility Technique only as Effective as the Natural Way
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2017)... ... June 24, 2017 , ... ... at the Sheraton Erie Bayfront and Erie Convention Center on June 8-10. ... exhibits, a student quiz bowl, award and scholarship presentations, and professional networking. ...
(Date:6/23/2017)... ... 23, 2017 , ... The Rhode Island Quality Institute (RIQI) ... and Dashboards, an innovative new service enabling healthcare providers to proactively coordinate care ... and Dashboards provide near real-time data about patients admitted to and/or discharged from ...
(Date:6/23/2017)... (PRWEB) , ... June 24, 2017 , ... Studies show ... significantly reduce the risk of visual loss in these patients. , But how often ... diet, or smoking cessation to patients at risk of or with early symptoms of ...
(Date:6/23/2017)... ... ... Everybody has their own personal preference when it comes to pornography. Some ... don't like it at all. FindaTopDoc took a look at what makes people attracted ... readers a taste of their deepest, darkest fantasies and has the ability to help ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... Cancer Conference from Sept. 18 to 20. , The two-day conference is focused ... with the goal of improving patients’ lives and eliminating racial breast cancer-related disparities. ...
Breaking Medicine News(10 mins):
(Date:6/13/2017)... June 13, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that the U.S. Food and Drug Administration (FDA) has ... 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter related ... facility is a measure of the progress we have made ...
(Date:6/11/2017)... and Company (NYSE: LLY ) announced today ... an investigational treatment for the prevention of episodic and ... endpoints for galcanezumab compared to placebo at both studied ... REGAIN) will be presented today at the American Headache ... . "The detailed Phase 3 ...
(Date:6/9/2017)... PALO ALTO, Calif. , June 9, 2017 /PRNewswire/ ... medical device company focused on the design, manufacture, sale ... updated the market on the progress of its commercial ... AeroForm is now available in more than one hundred ... country. AeroForm offers a needle-free alternative ...
Breaking Medicine Technology: